Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
about
Solution structure of the major factor VIII binding region on von Willebrand factorDesmopressin in the treatment of women's bleeding disorders.Haemophilia A and haemophilia B: molecular insightsPhosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a miceThe "normal" factor VIII concentration in plasma.Haemophilias: advances towards genetic engineering replacement therapy.Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimerasImmunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study.A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.Genetic linkage of two intragenic restriction fragment length polymorphisms with von Willebrand's disease type IIA. Evidence for a defect in the von Willebrand factor geneUtility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice.A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.Cloning and characterization of two cDNAs coding for human von Willebrand factor.Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene.Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.von Willebrand factor biosynthesis and processing.On the versatility of von Willebrand factorInteraction between VWF and FVIII in treating VWD.Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.Gene deletions correlate with the development of alloantibodies in von Willebrand disease.Pathogenesis, clinical picture and treatment of von Willebrand's disease.The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2.Preparation of pooled cryoprecipitate for treatment of hemophilia A in a home care program.Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.Haemophilia A and haemophilia B: molecular insights.
P2860
Q27682916-6C20436E-F0FC-4A3B-BD3E-8B0C1F7293D5Q33723752-3EE1A2C2-E00D-42DD-B300-DD22AE2B2E4EQ33918888-08532657-A884-4933-B384-A3BBA539E41EQ33954639-4F27ACDC-41E2-4AAD-9D07-E588A25FF655Q34023313-427850E5-FD8C-49FB-A20D-E8CFD52E29BEQ34229310-2CA5E7A2-EEE8-42F2-B911-C1C886F4B168Q34468951-942CFB48-7CE9-4D47-BC13-84F14722A337Q34744656-23A9C6DF-6C0E-4B23-8D3B-FFB03F5F2BD0Q35601547-F3B4A164-4CFB-47DF-8C47-E184F4C1EB9BQ35802242-8EC76560-77CF-4A40-BBE7-1BFD614F653CQ35804461-666FB5DF-A042-4E09-9B7A-9A65CACCD168Q35811246-A4186E77-8B01-418A-B680-5613ABDA80C6Q35846930-60688950-49E6-4C73-B840-2C76596E21D3Q36250957-3AF70BA1-A6E2-4A98-9B66-0A29A8956A94Q36413864-1EA55F46-EB82-4F36-9964-2022895D951AQ36487665-FF3672CB-7EA3-467E-B585-57F22A52AABDQ36768042-D1ECB683-99C3-4DAD-B429-299D5F45F968Q37552867-84D73F05-2E77-4EED-BDD5-AA13559DC20AQ37711742-21C8EB04-5B55-4F9F-83FC-BABA5D704301Q38128303-A06353CF-54B4-488C-B203-68ADFDE6B852Q38326080-768C6182-EE66-4FB0-9C35-5EBBD325320EQ38953180-62E05A2E-6BFA-4391-BDFA-2EB5EF581BC3Q39631688-01703B2F-CF41-4BCC-AD00-3655C3C3BC53Q39677665-84980F18-080D-4902-8383-C4930FB4B256Q40922128-D5E06143-F1FB-4C23-B42F-7166F33CFA84Q40999861-5F6C10FA-2978-4E8B-8A49-D5122A222C32Q41695401-B06EBC41-8A7C-4275-A662-C1509B8D78DEQ45856645-B210AD87-9804-4FF5-B9BA-CD5C2C7BCB5FQ45862750-245E3F3B-18DD-478E-AFF4-B16C78DCBBBFQ45871507-5BEE8845-0B0A-44E6-8A63-EFDACB0B779BQ45878358-4AAA1665-B0BD-43CE-866A-D189E08D3030Q50959137-972B12E8-789C-4B1B-80A9-DAA244B40A3FQ53315892-75F26B0E-5BD6-40B7-97C4-8ED10D3D83F3
P2860
Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh-hant
name
Response to infusions of polye ...... and von Willebrand's disease.
@en
Response to infusions of polye ...... and von Willebrand's disease.
@nl
type
label
Response to infusions of polye ...... and von Willebrand's disease.
@en
Response to infusions of polye ...... and von Willebrand's disease.
@nl
prefLabel
Response to infusions of polye ...... and von Willebrand's disease.
@en
Response to infusions of polye ...... and von Willebrand's disease.
@nl
P2093
P2860
P921
P1476
Response to infusions of polye ...... and von Willebrand's disease.
@en
P2093
Johnson AJ
Kernoff PB
Middleton S
Tuddenham EG
P2860
P304
P356
10.1111/J.1365-2141.1982.TB03888.X
P407
P577
1982-10-01T00:00:00Z